Biosplice (was Samumed) � SM04690 Osteoarthritis of the hip

Biosplice’s mission is to restore health by delivering first-in-class therapies that harness alternative splicing. Their scientific platform is based on biological discoveries that govern tissue specialization and enable selective elimination of harmful proteins using small molecules. Biosplice has uncovered insights enabling Wnt pathway modulation that have unlocked the broad therapeutic potential of alternative splicing by targeting the CLK/DYRK family kinases. These kinases govern the selection of tissue-specific and disease-selective RNA splice-sites, thus defining them as targets for drug therapy. Selectively reprogramming cellular behavior could lead to the discovery of new, potentially curative therapies for certain diseases. Biosplice’s clinical pipeline is focused on osteoarthritis and oncology, with early-stage programs in neurology and other areas of significant unmet medical need. Biosplice has developed six different compounds with fourteen different indications currently being explored in either preclinical or clinical trials. Pan-CLK/DYRK is a family of protein kinases that may be targeted by SM04690, also known as lorecivivint. Lorecivivint uses a novel mechanism of Wnt pathway inhibition, chondrocyte was presented at ACR 2019 demonstrated its ability to improve pain and function out to 12 months in most patients. Lorecivivint for osteoarthritis of the hip is entering Phase I of clinical trials but are expected to accelerate through Phase III due to the prior success of SM04690 in treating osteoarthritis of the knee